NCT01705223View on ClinicalTrials.gov

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

January 31, 2015

Conditions
AIDS
Interventions
BIOLOGICAL

DNA vaccine

4mg/dose, three doses at week 0,4,8

BIOLOGICAL

DNA vaccine prime with the addition of electroporation

4mg/dose, three doses at week 0,4,8

BIOLOGICAL

rTV boost

at week 16

BIOLOGICAL

rTV boost

at week 24

BIOLOGICAL

rTV boost

at week 32

Trial Locations (1)

Unknown

Beijing Youan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

National Center for AIDS/STD Control and Prevention, China CDC

OTHER_GOV

NCT01705223 - Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) | Biotech Hunter | Biotech Hunter